Why carry out this study?

Retinal ischemia, thought to be the mediator in most cases of neovascular glaucoma, results in the release of angiogenic factors, such as vascular endothelial growth factor (VEGF), which trigger neovascularization.

It has been suggested that intravitreal anti-VEGF agents may improve intraocular pressure (IOP) and neovascularization in patients with neovascular glaucoma.

The VENERA study was designed to assess the efficacy and safety of intravitreal aflibercept (IVT-AFL) in patients with neovascular glaucoma in the absence of systemic IOP-lowering drugs and panretinal photocoagulation.

What was learned from the study?

Patients who received IVT-AFL (without systemic IOP-lowering drugs) showed a statistically and clinically significant decrease in mean IOP (mean change, −8.3 mmHg at week 1), and an improvement in neovascularization of the iris and angle (81.3% and 50.0% improved at week 1, respectively).

The incidence of treatment-emergent adverse events was consistent with the known safety profile for IVT-AFL.

These findings support the role of anti-VEGF agents, specifically IVT-AFL, in managing patients with neovascular glaucoma.